Filed by Solexa, Inc.
pursuant to Rule 425
under the Securities Act of 1933 and
deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: Solexa, Inc.
Commission File No. 000-22570
pursuant to Rule 425
under the Securities Act of 1933 and
deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: Solexa, Inc.
Commission File No. 000-22570
The following presentation materials relate to Illumina, Inc.:
| Jay Flatley President & CEO (c) 2006 Illumina, Inc. Illumina, Sentrix, Array of Arrays, BeadArray, DASL, Infinium, GoldenGate, iSelect, BeadXpress, VeraCode and Making Sense Out of Life are registered trademarks or trademarks of Illumina Inc. |
| Forward-Looking Statements This communication contains forward-looking statements that involve risks and uncertainties. Illumina, Inc. ("Illumina") and Solexa, Inc. ("Solexa") caution readers that any forward-looking information is not a guarantee of future performance and actual results could differ materially from those contained in the forward-looking information. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue" and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements include, but are not limited to, statements about the benefits of the transaction between Illumina and Solexa, future financial and operating results, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the ability to obtain regulatory approvals of the transaction on the proposed terms and schedule; the failure of Illumina or Solexa stockholders to approve the transaction; the failure of Illumina or Solexa to satisfy the other conditions to the transaction; the risk that the businesses will not be integrated successfully; the risk that the anticipated synergies and benefits from the transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues. Additional important factors that may affect future results are detailed in Illumina's and Solexa's filings with the Securities and Exchange Commission (the "SEC"), including their recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina and Solexa disclaim any intent or obligation to update these forward-looking statements. Additional Information In connection with the proposed merger, Illumina will file with the SEC a Registration Statement on Form S-4 that will include a joint proxy statement of Illumina and Solexa that also constitutes a prospectus of Illumina. Illumina and Solexa will mail the joint proxy statement/prospectus to their respective stockholders. Investors and security holders are urged to read the joint proxy statement/prospectus regarding the proposed merger when it becomes available because it will contain important information. You may obtain a free copy of the joint proxy statement/prospectus (when it is available) and other related documents filed by Illumina and Solexa with the SEC at the SEC's website at www.sec.gov. The joint proxy statement/prospectus (when it is available) and the other documents may also be obtained for free by accessing Illumina's website at www.illumina.com under the tab "Investors" and then under the heading "SEC Filings" or by accessing Solexa's website at www.solexa.com under the tab "Investors" and then under the heading "SEC Documents." Participants in the Solicitation Illumina and Solexa and their respective directors, executive officers and certain other members of management and employees may be soliciting proxies from stockholders in favor of the merger. Information regarding the persons who may, under the rules of the SEC, be considered participants in the solicitation of the stockholders in connection with the proposed merger will be set forth in the joint proxy statement/prospectus when it is filed with the SEC. You can find information about Illumina's executive officers and directors in Illumina's definitive proxy statement filed with the SEC on April 26, 2006. You can find information about Solexa's executive officers and directors in their definitive proxy statement filed with the SEC on August 31, 2006. You can obtain free copies of these documents by using the contact information provided at Illumina's or Solexa's website. |
| Our Mission: Provide the Tools that Help Enable Personalized Medicine DNA sequence raw data Medically valuable information Personalized Medicine |
| Large and Rapidly Growing Markets Research - gold rush to find disease genes associated with complex diseases Whole genome enabled by content and price Expansion into pharma and biotech - improving success rates Monitoring and diagnostic screening 2006 2010 Gene Expression 800 1000 SNP Genotyping 350 1000 Molecular Diagnostics 100 500 Gene Expression Molecular Diagnostics SNP Genotyping $1,250 $2,500 Total Market $ millions Source: Illumina estimates |
| Oligator(r) Core Technology Proprietary technology to manufacture oligos at high volume and low cost Key raw material for arrays and reagents Enabling for Invitrogen partnership |
| Sentrix(r) Array Matrix Sentrix(r) BeadChip Illumina's Core BeadArrayTM Technology |
| ? Custom Assays ? Linkage V4 ? MHC Panel Application Assay/Method Product Configurations Human-1 HumanHap300 HumanHap240s HumanHap550 ? 96 Samples x 1400 Genes ? 16 Samples x 1400 Genes GoldenGate(r) (96, 384, 768, 1536 Multiplex) InfiniumTM (Unlimited Multiplexing) Whole Genome (Direct Hybridization) Focused Sets (High Sample, Limited Genes) SNP Genotyping Gene Expression Broad and Rapidly Growing Application Suite ? Cancer Panel ? Mouse Linkage ? DNA Test Panel HumanHap550+ HumanHap650Y iSelect Custom Infinium Copy Number (CGH) DASLTM (Parafin Embedded Samples) 1536 User defined genes Universal array ? Human 6, Human RefSeq 8 Mouse 6, Mouse 8 Rat 12 |
| Illumina BeadStation / BeadLab |
| Servers Reagents Robots SOPs Illumina BeadStation / BeadLab |
| Illumina BeadStation / BeadLab |
| Whole Genome Genotyping Infinium Assay |
| InfiniumTM Whole Genome Genotyping Assay Sets Market Standard for Quality and Performance Robust, single tube assay with no PCR Single chip Full automation support Ability for "intelligent SNP selection" Use of HapMap data HapTag Block Highest information content |
| InfiniumTM Product Family Q206 Q106 Q405 Q305 Q306 |
| InfiniumTM Product Family Q206 Q106 Q405 Q305 Q306 |
| InfiniumTM Product Family Q206 Q106 Q405 Q305 Q306 |
| HumanHap300-Duo and HumanHap300-Duo+ World's first multi-sample whole genome arrays Based on HumanHap300 content with two samples per chip Streamlines workflow, reduces labor and improves convenience 7th and 8th products launched in Infinium family this year |
| Recent Deal Summary Customer Disease # Samples Product North Shore IBD consortium 2,000 HumanHap300 Genizon 15-20 common 16,000 HumanHap300+ GlaxoSmithKline Not disclosed 2,000 HumanHap550* Mass Gen/Harvard ALS 2,200 HumanHap300 Bovine Consortium Breeding 10,000 iSelect Std. product deCODE Various 100,000 HumanHap300 CHOP Children's diseases 30,000 HumanHap550 Duke University Autism 1,800 HumanHap550 Top 5 Pharma Not disclosed 3,200 initially HumanHap650Y Amgen Woman's Health 28,000 HumanHap300 Duo * Indicates work done under services contract |
| Erasmus Medical Center Netherlands largest medical facility 10,000 samples using HumanHap550 2 BeadStations Rotterdam Study - a prospectively monitored 17 year cohort Studying late-age diseases including neurological, cardiovascular, endocrine, locomotor and ophthalmological conditions |
| Large Opportunity in Gene Expression |
| Comprehensive Suite of Gene Expression Products Screening Toxicology Dx panels Cell cultures Fresh tissue Paraffin Embedded Tissue Biomarkers discovery |
| Micro Array Quality Control (MAQC) Project Goal to generate a set of quality control tools and standards 137 participants 51 organizations (including all commercial expression microarray vendors) FDA, NIH, EPA, USDA www.nature.com/nbt/focus/maqc/index.html Key conclusion: Microarray gene expression data from different commercial platforms are directly comparable Illumina's BeadChips consistently among the very best performers across the various technical measurements Implication: Vendor selection need not be constrained by legacy data but based on value, ease of use, quality of content and customer service |
| Opening New Markets |
| Clarifying the Nomenclature First System Based on VeraCode Technology Digital Microbead Technology CyVera Company Purchased April 2005 |
| Market Needs Drug efficacy Patient stratifications Clinical trials Disease staging & subtyping Clinical trial patient selection POC Molecular diagnostics R&D Targeted treatment Personalized medicine Theranostics Basic biology of disorders, pathways, hormonal signaling Overall genetic functionality & regulatory network SNP/Haplotype Discovery/Mapping Drug pathway validation Drug-drug interaction Identify specific genes of interest, e.g. drug pathways, etc. Focused SNPs/Haplotypes R&D/DISCOVERY ARRAY DENSITY 1 to 100 100 to 500 100 to 5K 5K to 650K FOCUSED ASSAYS (PHARMA & BIOTECH COS.) DIAGNOSTICS BIOMARKER VALIDATION CLINICAL SCREENING MOLECULAR DIAGNOSTICS |
| (c) 2006 Illumina, Inc. Illumina, Sentrix, Array of Arrays, BeadArray, DASL, Infinium, GoldenGate, iSelect, BeadXpress, VeraCode and Making Sense Out of Life are registered trademarks or trademarks of Illumina Inc. |
| Technology / Platform Synergy Discovery Research Focused Research Molecular Diagnostics WG genotyping WG expression Biomarker discovery Future WG applications Custom genotyping Focused expression DASL Biomarker discovery Low/mid density GT/GEX Protein applications Biomarker screening Biomarker panels |
| Digital Code Generation CODE IMAGE 1 0 1 1 0 1 0 1 0 0 0 0 1 0 1 BINARY CODE DECIMAL CODE = 41133 CODE GENERATED BY CREATING EMBEDDED HOLOGRAPHIC DIFFRACTIVE ELEMENTS Glass Surface of Beads Ideal for Bioassays High Density Codes Easily Imprinted (24 bit) Virtually Unlimited Multiplexing CONVENTIONAL CCD CAMERA BEAD "READING" BEAM |
| (c) 2006 Illumina, Inc. Illumina, Sentrix, Array of Arrays, BeadArray, DASL, Infinium, GoldenGate, iSelect, BeadXpress, VeraCode and Making Sense Out of Life are registered trademarks or trademarks of Illumina Inc. |
| BeadXpress Reader INSTRUMENT SPECIFICATIONS SAMPLE DELIVERY FORMAT Standard 96-well plate MULTIPLEXING PER SINGLE WELL 1 to 384 THROUGHPUT 120 samples/hr at 10-plex 80 samples/hr at 96-plex DETECTION Optional 1 or 2 color detection AUTOMATION Designed to be compatible with standard laboratory automation LIMS compatible ASSAY BEAD KIT SAMPLE PLATE ASSAY CODE LIBRARY DATA & LOG FILES |
| Eight Wells Read in Parallel EIGHT WELLS ARE SAMPLED SIMULTANEOUSLY AND MICROBEADS ARE TRANSFERRED INTO A MULTI-SECTORED READER CELL. |
| Beads Align in Groove Plate GROOVE PLATE CROSS-SECTION BEADS FALL INTO GROOVE PLATE CAPILLARY FORCE ATTRACTS BEADS INTO GROOVES BEADS ALIGN TIGHTLY FOR OPTIMAL SCANNING EFFICIENCY |
| Code Detection BEAD "READING" BEAM CCD LINE ARRAY |
| Flush Cycle FOLLOWING READOUT, THE BEADS ARE FLUSHED FROM THE READER CELL USING A SECOND ACTUATION PRESSURE CYCLE. |
| A Flexible Platform for Multiple Applications 100000 10000 1000 100 10 1 0.1 1 10 100 1000 10000 Conc (pM) Counts Analyte Fit 3-sigma LOD GENE EXPRESSION PROTEIN EXPRESSION GENOTYPING |
| GoldenGate Genotyping Assay (96 & 384-plex) OPAs + Reagents GoldenGate Genotyping User Manual (RUO) GOLDENGATE GENOTYPING + Beads Pooled in 96-well Plates (96 & 384-plex/well) USER MANUAL IN DEVELOPMENT |
| Universal Capture Bead Sets Unique Bead Code Types in Tubes Assay Design Guidelines (RUO) CUSTOMER DEVELOPED HOMEBREW + GUIDELINES IN DEVELOPMENT Customer controls level of multiplexing and number of samples |
| Carboxyl Bead Sets (Protein Assays) Unique Bead Code Types in Tubes Assay Design Guidelines (RUO) CUSTOMER DEVELOPED HOMEBREW + GUIDELINES IN DEVELOPMENT Customer controls level of multiplexing and number of samples |
| Rollout Q4 Q3 Q3 Q2 Q1 Q4 Q2 Q1 Q4 Q3 Q2 Q1 ISO 13485 Assay/SW Dev - 510K Clinical Trial Commercialization Novel Marker Validation Clinical Trials for PMA(s) System Launch RUO-Home Brew, Novel Marker Discovery, Validation Research Market - Existing Customer Base Field Testing System & Assay Development System & Assay Development 2006 2007 2008 |
| Diagnostic Partnerships deCODE Myocardial infarction Type II diabetes Breast cancer ReaMetrix Will develop diagnostic assays on BeadXpress ReaMetrix to market in India Illumina has marketing rights outside India Genizon Rights to markers resulting from study of atherosclerosis |
| Worldwide Sales and Support Network Worldwide Sales and Support Network 33 Direct sales Distributors - Australia/NZ, China, India, Malaysia, South Korea, Taiwan, Thailand, Poland, Spain 58 Technical support |
| Revenue $53,472 $ 19,516 $ 73,501 COGS 15,939 6,599 23,181 Gross Margin 37,533 12,917 50,320 % 70.2% 66.2% 68.5% R&D 6,790 7,062 27,725 SG&A 11,734 7,276 27,972 Net Income* 19,917 (1,309) (20,874)** EPS* $0.39 $(0.03) $(0.52)** Non-GAAP Q3 Financial Performance Note: All Numbers in Thousands. (*) Excludes charges (**) Includes one-time write off of in-process R&D for CyVera of $15,800. Q3 2006 Q3 2005 FY 2005 21 Consecutive Quarters of Revenue Growth 174% Revenue Growth YoY 37.2% Net Income |
| Summary Multi-billion dollar opportunity in research and molecular diagnostics markets BeadArray technology is fundamentally flexible, low-cost and scalable Our portfolio of products is growing quickly enabled by a well developed infrastructure and innovative assay technology The VeraCode technology addresses the emerging markets in biomarker detection and molecular diagnostics 21 sequential quarters of revenue growth with strong profitability |
